


Progress with the global implementation of current WHO recommendations on Hib vaccines



Hanuman and the mountain of sweets. Mysore painting

1.5 million deaths among children from vaccine preventable disease by WHO regions, 2008



Source: Black RE at all, Global, regional, and national causes of child mortality in 2008: a systematic analysis, Lancet. 2010 Jun 5;375(9730):1969-87. Epub 2010 May 11.

* WHO/IVB estimates , March 2012

SAGE recommendations on Hib vaccines

2000 - Hib vaccine use limited to high income countries.

2002 / 3 / 4 - SAGE recommended consultation with regions, esp WPR, SEA and AFR, concerning burden and use of Hib vaccine.


2005 - SAGE recommended global introduction of Hib vaccine.

2006 - WHO position paper published.

2010 - SAGE recognised need to work with large countries to implement recommended policies.

Countries which had / have introduced Hib-containing vaccines

1999
(61 countries)



Introduced* (61 countries or 25%)
Not Introduced (143 countries or 74%)
Not available
Not applicable

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not be full agreement.


Data Source: Joint Reporting Form, 2011 and NUVI database

Map production: Immunization Vaccines and Biologicals, (IVB), World Health Organization

Date of slide: 11 May 2012

* Includes partial introductions

2012
(179 countries)



Introduced* (179 countries or 92%)
Planned introduction in 2012 (6 countries or 3%)
Planned introduction in 2013 (4 countries or 2%)
Not Introduced (5 countries or 3%)
Not available
Not applicable

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not be full agreement.

Data Source: Joint Reporting Form, 2011 and NUVI database


Map production: Immunization Vaccines and Biologicals, (IVB), World Health Organization

Date of slide: 11 September 2012

* Includes partial introductions

Global coverage estimates 1980-2011

DTP1, DTP3, Measles, HepB3, Hib3, PCV3 and Rota



43%

Prequalified pentavalent (DTwP-Hep B-Hib)

Vaccine	Manufacturer/country	Presentation
Fully liquid	Berna Biotec a Crucel company Korea	1 dose vial
Fully liquid	Biological E India	1 and 10 dose vials
Fully liquid	SII India	1, 2 and 10 dose vials
Lyo-liquid	Biological E	1 and 10 dose vials
Lyo-liquid	GSK Belgium	1 and 2 dose vials
Lyo-liquid	SII India	1 and 10 dose vials
Lyo-liquid	LG Korea	1 and 2 dose vials

Hib - containing vaccines: cost *per dose* (UNICEF supply division)

Presentation	Supplier Name	DTP - Hep B - Hib	
		2001	2011
DTP-HepB-Hib vaccine in a single dose liquid presentation	Crucell Switzerland AG		\$2.8000- \$3.2000
	Panacea Biotech Ltd.		\$2.9650
	Shantha Biotechnics Ltd.		
	Serum Institute Of India Ltd.		\$2.2500- \$2.5000
DTP-HepB-Hib vaccine in a ten dose liquid presentation	Serum Institute Of India Ltd.		\$1.7500- \$2.1050
DTP-HepB-Hib vaccine in a two dose lyophilised presentation	Serum Institute Of India Ltd.		\$2.2500
	GlaxoSmithKline Biologicals S.A.	\$3.5000	\$2.9500

Data shows awarded price per dose (in US\$) per product per supplier per calendar year, based on contract commencement.

Where contracts include a range of prices during a calendar year period or for different countries or groups of countries, prices will be shown as a range.

Any financial discounts not included, e.g. due to expedited payments.

Where a supplier has not yet agreed to publish historical prices, it is indicated in the table above.

Data shows prices for deliveries on both FCA and CPT incoterms.

Last updated 13 January 2012.

Hib vaccine recommendations, 2006

(http://www.who.int/immunization/policy/Immunization_routine_table2.pdf)

<i>Haemophilus influenzae</i> type b	Age at 1st dose	Doses in primary series	Interval between doses	
			1st to 2nd	2nd to 3 rd
	6 weeks (min) with DTP1, 24 months (max)	3	4 weeks (min) with DTP2	4 weeks (min) with DTP3

Catch-up vaccination of children 12 – 24 months: a single dose is sufficient

Booster dose (recommended at 12–18 months of age in many developed countries) : the need for and timing of booster in developing countries have not yet been defined.

Individuals aged >24 months at high risk of Hib disease: should be vaccinated where resources are available.

Current DTP and measles schedules

Approx:

1 / 3 of countries with 6-10-14 week / 9 month schedule

1 / 3 of countries with 2-4-6 month / 12 month schedule

1 / 3 of countries with a variety of other schedules

